FDA Determines Regulatory Review Period for Rapamune Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the review period for a patent extension application for Rapamune, a human drug product, as required by law, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.